Alzheimer's disease is a complex neurodegenerative disorder that affects millions of people worldwide. While there is no cure for the disease, ongoing research efforts have led to significant advancements in our understanding of the underlying mechanisms that drive the disease.
Multiple Sclerosis (MS) is an unpredictable neurological condition which affects the brain and spinal cord, potentially causing a wide range of symptoms including problems with vision, arm or leg movements, sensation, and balance. Multiple Sclerosis (MS) is the most common autoimmune disorder of the Central Nervous System (CNS), affecting around 2.
CHDI’s 17th Annual Therapeutics Conference: Event ReviewBy Ronald Ramos (Senior Director, Business Development) and Kirsi Kinnunen (Senior Biomarker Scientist) CHDI’s 17th Annual HD Therapeutics Conference finally returned to a full, in-person event for the first time since 2020.
The Global Alzheimer's Platform Foundation’s GAP-Net Site Optimization Conference 2022 gave all participants an update on the important Bio-Hermes trial which is going very well. This year’s conference was a highly collaborative event with many interesting presentations and discussions on issues related to research in Alzheimer’s Disease.
Interview with IXICO & GAP Foundation: Alzheimer’s Disease & the Pioneering Bio-Hermes StudyAlzheimer's disease is an irreversible, progressive brain disorder that accounts for about 50–75% of all cases of dementia. It’s a growing problem. The USA saw a 145% increase in Alzheimer’s disease-related deaths between 2000 and 2018.
What is IXIQ. Ai? Find out from our Chief Scientific Officer Robin WolzThis month, we launch into production on its first clinical trials. IXIQ. Ai is the next generation of our technology platform which we have been developing for more than a decade.
We are delighted to be working with the Global Alzheimer's Platform Foundation and their industry partners for the pioneering Bio-Hermes study. Watch the interview with IXICO's clinical development advisor Lynne Hughes and President of GAP John Dwyer as they discuss this partnership and the study.
Romina Oxborough recently joined the IXICO team as Senior Vice President of Operations, bringing a wealth of experience in developing strategic services underpinned by operational delivery. We spoke to Romina about her experience so far at IXICO and the main thing that gets her out of bed in the morning. Hi Romina.
A life science professional with over 20 years of industry experience, Ron joined our team this year in our Business Development department. His experience spans the entire drug development pipeline and is passionate about changing patients’ lives for the better.
Parkinsonism is a movement disorder, although not always due to Parkinson disease. There are many neurological disorders that present with similar movement abnormalities. Although the differential diagnosis is mostly clinical between these different disorders, imaging biomarkers play a role and also have the potential to track disease progression.
1-10 of 16 results